<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108614</url>
  </required_header>
  <id_info>
    <org_study_id>Drug Users Intervention</org_study_id>
    <secondary_id>2008ZX10001-016</secondary_id>
    <nct_id>NCT01108614</nct_id>
  </id_info>
  <brief_title>Injecting Drug Use Community Intervention Trial</brief_title>
  <official_title>A Randomized Community Intervention Trial on Reducing HIV Infection Among Drug Users Attending Methadone Maintenance Treatment(MMT) and Preventing Secondary Transmission From HIV Positive Clients to Their Sexual Partners in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for AIDS/STD Control and Prevention, China CDC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yunnan Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinjiang Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for AIDS/STD Control and Prevention, China CDC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to reduce the HIV/HCV incidence among the clients attending
      community-based methadone maintenance treatment (MMT) , and to prevent the secondary sexual
      transmission from HIV+ clients to their spouse and sex partners, through intensified
      comprehensive intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Even though National sentinel surveillance data show that the increase rate of HIV new
      infections among IDUs in China has become stabilized and slowed down, the new HIV infection
      is still on the rise, especially in the Yunnan, Guizhou, Guangxi, Xinjiang and Sichuan. This
      study attempts to further reduce the new infection among MMT clients, and particularly to
      prevent the transmission from HIV infected clients to their sexual partners with
      comprehensive intervention.

      The purposes of this study are:

        1. To evaluate the effectiveness of comprehensive interventions to decrease the HIV/STIs
           incidence among MMT clients.

        2. To prevent the sexual transmission between those HIV+ clients and their spouse/partners
           with intensified intervention.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV incidence rate</measure>
    <time_frame>August 1,2009 to 31,Mar,2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCV, Syphilis, HSV-2 incidence</measure>
    <time_frame>1,Aug.,2009 to 31,Mar,2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMT Retention Rate and Lapse/Relapse Rate</measure>
    <time_frame>1,Aug.,2009 to 31,Mar,2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of condom uses</measure>
    <time_frame>1,Aug.,2009 to 31, Mar,2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The awareness of HIV-related Information among the clients [</measure>
    <time_frame>1,Aug.,2009 to 31,Mar,2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of discordant couple/partners receiving HIV testing</measure>
    <time_frame>1,Aug.,2009 to 31,Dec,2010</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <condition>Syphilis</condition>
  <condition>HSV-2</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine HIV prevention, including health education, counseling and testing, condom promotion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intervention</intervention_name>
    <description>Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Comprehensive intervention group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        (1) For MMT clients:

        Inclusion Criteria:

          -  20 years or above and have independent capacity of civil conduct.

          -  Those have enrolled in MMT clinics more than one month, and progressed to the phase of
             maintenance treatment.

          -  No mental and other physical diseases

          -  More than 6-month stay at local places and registered at the designated clinics.

          -  Complete Informed consent

        Exclusion Criteria:

          -  Fail to complete Informed consent

          -  Temporarily transit in or out of the designated clinic.

          -  Those have enrolled in MMT clinics less than one month, and haven't progressed to the
             phase of maintenance treatment.

          -  With serious mental or other physical diseases

        For the spouse or sex partners of MMT HIV+ clients'

        Inclusion Criteria:

          -  20 years or above and have independent capacity of civil conduct.

          -  Keep fixed sexual contact with HIV+ clients in the recent 6 month

          -  No mental and other physical diseases

          -  More than 6-month stay at local places and be able to participate the 1 year follow
             up.

          -  Complete Informed consent

          -  The recent HIV test is negative

        Exclusion Criteria:

          -  Fail to complete Informed consent

          -  Temporarily transit in or out of the designated clinic.

          -  With serious mental or other physical diseases

          -  The recent HIV test is positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zunyou Wu, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for AIDS/STD Control and Prevention, China CDC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zunyou Wu, MD, PHD</last_name>
    <phone>86-10-58900900</phone>
    <email>wuzy@chinacdc.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenyuan Yin, MD, MS</last_name>
    <phone>86-10-58900951</phone>
    <email>yinwy928@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention,Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <zip>530028</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Liu, MD</last_name>
      <phone>0771-2518838</phone>
      <email>lw_gx@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Rongjian, MD</last_name>
      <phone>0771-2528838</phone>
      <email>gxlrj@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wei Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention, Guizhou Province</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Limei Shen, MD</last_name>
      <phone>0851-6823903</phone>
      <email>shenlm999@tom.com</email>
    </contact>
    <contact_backup>
      <last_name>Yongming Yao, MD</last_name>
      <phone>0851-6820035</phone>
      <email>yaoyongming667@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Limei Shen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention, Sichuan Province</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linglin Zhang, MD</last_name>
      <phone>028-85589207</phone>
      <email>weirzhang@vip.163.com</email>
    </contact>
    <contact_backup>
      <last_name>Lai Wenhong, MD,MS</last_name>
      <phone>028-85581160</phone>
      <email>sclwh66@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Linglin Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention, Xingjiang Uyghur Autonomous Region</name>
      <address>
        <city>Urumchi</city>
        <state>Xingjiang Uyghur Autonomous Region</state>
        <zip>830002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fan Li, MD</last_name>
      <phone>0991-3822696</phone>
      <email>xjfanli@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Feng Zhang, MD,MS</last_name>
      <phone>0991-8569907</phone>
      <email>xjabzf@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fan Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Disease Control and Prevention, Yunnan Province</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manhong Jia, MD</last_name>
      <phone>0871-3626304</phone>
      <email>jmanhong@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wanyue Zhang, MD</last_name>
      <phone>0871-3630775</phone>
    </contact_backup>
    <investigator>
      <last_name>Manhong Jia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.nmp.gov.cn/index.htm</url>
    <description>National Science and Technology Project</description>
  </link>
  <reference>
    <citation>Costenbader EC, Astone NM, Latkin CA. The dynamics of injection drug users' personal networks and HIV risk behaviors. Addiction. 2006 Jul;101(7):1003-13.</citation>
    <PMID>16771892</PMID>
  </reference>
  <reference>
    <citation>Booth RE, Corsi KF, Mikulich-Gilbertson SK. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend. 2004 May 10;74(2):177-85.</citation>
    <PMID>15099661</PMID>
  </reference>
  <reference>
    <citation>Gifford E, Humphreys K. The psychological science of addiction. Addiction. 2007 Mar;102(3):352-61.</citation>
    <PMID>17298641</PMID>
  </reference>
  <reference>
    <citation>Gyarmathy VA, Neaigus A. Marginalized and socially integrated groups of IDUs in Hungary: potential bridges of HIV infection. J Urban Health. 2005 Sep;82(3 Suppl 4):iv101-12.</citation>
    <PMID>16107433</PMID>
  </reference>
  <reference>
    <citation>Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003 Jul;22(4):332-9.</citation>
    <PMID>12940388</PMID>
  </reference>
  <reference>
    <citation>Lloyd JJ, Ricketts EP, Strathdee SA, Cornelius LJ, Bishai D, Huettner S, Havens JR, Latkin C. Social contextual factors associated with entry into opiate agonist treatment among injection drug users. Am J Drug Alcohol Abuse. 2005;31(4):555-70.</citation>
    <PMID>16320434</PMID>
  </reference>
  <reference>
    <citation>Termorshuizen F, Krol A, Prins M, Geskus R, van den Brink W, van Ameijden EJ. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend. 2005 Aug 1;79(2):231-40. Epub 2005 Feb 24.</citation>
    <PMID>16002032</PMID>
  </reference>
  <reference>
    <citation>International Harm Reduction Development Program of the Open Society Institute. Saving lives by reducing harm: HIV prevention and treatment for injecting drug users. New York City, USA; 2006.</citation>
  </reference>
  <reference>
    <citation>Ball A, Beg M, Doupe A, Weiler G. World Health Organization, Evidence for Action for HIV Prevention, Treatment and Care among Injecting Drug Users. The International Journal of Drug Policy. 2005;16.</citation>
  </reference>
  <reference>
    <citation>de la Fuente L, Bravo MJ, Lew C, Barrio G, Soriano V, Royuela L. [The prevalence of human immunodeficiency virus infection and the risk behaviors in the heroin addicts of Barcelona, Madrid and Seville: an example of the advantages of centering studies on addicts and not just on intravenous users]. Med Clin (Barc). 1999 Nov 20;113(17):646-51. Spanish.</citation>
    <PMID>10618778</PMID>
  </reference>
  <reference>
    <citation>Welp EA, Lodder AC, Langendam MW, Coutinho RA, van Ameijden EJ. HIV prevalence and risk behaviour in young drug users in Amsterdam. AIDS. 2002 Jun 14;16(9):1279-84.</citation>
    <PMID>12045494</PMID>
  </reference>
  <reference>
    <citation>Garfein RS, Monterroso ER, Tong TC, Vlahov D, Des Jarlais DC, Selwyn P, Kerndt PR, Word C, Fernando MD, Ouellet LJ, Holmberg SD. Comparison of HIV infection risk behaviors among injection drug users from East and West Coast US cities. J Urban Health. 2004 Jun;81(2):260-7.</citation>
    <PMID>15136659</PMID>
  </reference>
  <reference>
    <citation>Gilman SM, Galanter M, Dermatis H. Methadone Anonymous: A 12-Step Program for Methadone Maintained Heroin Addicts. Subst Abus. 2001 Dec;22(4):247-256.</citation>
    <PMID>12466684</PMID>
  </reference>
  <reference>
    <citation>Gogineni A, Stein MD, Friedmann PD. Social relationships and intravenous drug use among methadone maintenance patients. Drug Alcohol Depend. 2001 Sep 1;64(1):47-53.</citation>
    <PMID>11470340</PMID>
  </reference>
  <reference>
    <citation>Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep. 1998 Jun;113 Suppl 1:107-15.</citation>
    <PMID>9722816</PMID>
  </reference>
  <reference>
    <citation>Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. Methadone maintenance and cessation of injecting drug use: results from the Amsterdam Cohort Study. Addiction. 2000 Apr;95(4):591-600.</citation>
    <PMID>10829334</PMID>
  </reference>
  <reference>
    <citation>Lansky A, Abdul-Quader AS, Cribbin M, Hall T, Finlayson TJ, Garfein RS, Lin LS, Sullivan PS. Developing an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System. Public Health Rep. 2007;122 Suppl 1:48-55.</citation>
    <PMID>17354527</PMID>
  </reference>
  <reference>
    <citation>Brady JE, Friedman SR, Cooper HL, Flom PL, Tempalski B, Gostnell K. Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002. J Urban Health. 2008 May;85(3):323-51. doi: 10.1007/s11524-007-9248-5. Epub 2008 Mar 15.</citation>
    <PMID>18344002</PMID>
  </reference>
  <reference>
    <citation>Des Jarlais DC, Braine N, Yi H, Turner C. Residual injection risk behavior, HIV infection, and the evaluation of syringe exchange programs. AIDS Educ Prev. 2007 Apr;19(2):111-23.</citation>
    <PMID>17411414</PMID>
  </reference>
  <reference>
    <citation>Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med. 2008 Jun;70(5):606-11. doi: 10.1097/PSY.0b013e3181772157. Epub 2008 Jun 2. Review.</citation>
    <PMID>18519886</PMID>
  </reference>
  <reference>
    <citation>Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004145. doi: 10.1002/14651858.CD004145.pub3. Review. Update in: Cochrane Database Syst Rev. 2011;(8):CD004145.</citation>
    <PMID>18425898</PMID>
  </reference>
  <reference>
    <citation>Gossop M, Marsden J, Stewart D, Rolfe A. Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend. 2000 Nov 1;60(3):275-86.</citation>
    <PMID>11053762</PMID>
  </reference>
  <reference>
    <citation>King VL, Kidorf MS, Stoller KB, Brooner RK. Influence of psychiatric comorbidity on HIV risk behaviors: changes during drug abuse treatment. J Addict Dis. 2000;19(4):65-83.</citation>
    <PMID>11110066</PMID>
  </reference>
  <reference>
    <citation>Strang J, Marsden J, Cummins M, Farrell M, Finch E, Gossop M, Stewart D, Welch S. Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. Addiction. 2000 Nov;95(11):1631-45.</citation>
    <PMID>11219367</PMID>
  </reference>
  <reference>
    <citation>Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol. 2003 Mar;22(2):223-8.</citation>
    <PMID>12683743</PMID>
  </reference>
  <reference>
    <citation>Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000 Jul;90(7):1100-11.</citation>
    <PMID>10897189</PMID>
  </reference>
  <reference>
    <citation>Beckett M, Burnam A, Collins RL, Kanouse DE, Beckman R. Substance use and high-risk sex among people with HIV: a comparison across exposure groups. AIDS Behav. 2003 Jun;7(2):209-19.</citation>
    <PMID>14586205</PMID>
  </reference>
  <reference>
    <citation>Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry. 2000 Apr;57(4):395-404.</citation>
    <PMID>10768702</PMID>
  </reference>
  <reference>
    <citation>Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, Banys P, Hall SM. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000 Mar 8;283(10):1303-10.</citation>
    <PMID>10714729</PMID>
  </reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2010</study_first_posted>
  <last_update_submitted>May 6, 2010</last_update_submitted>
  <last_update_submitted_qc>May 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Zunyou Wu</name_title>
    <organization>National Center for AIDS/STD Control and Prevention, China CDC</organization>
  </responsible_party>
  <keyword>Methadone maintenance treatment</keyword>
  <keyword>drug users</keyword>
  <keyword>heroin</keyword>
  <keyword>HIV</keyword>
  <keyword>HCV</keyword>
  <keyword>Syphilis</keyword>
  <keyword>HSV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

